IgG4-Related Lymphadenopathy Mimicking Mediastinal Lymph Node Metastasis of Lung Cancer on 18F-FDG PET/CT

Abstract

We report a case of a 73-year-old man with minimally invasive lung adenocarcinoma, post-resection, evaluated with ¹⁸F-FDG PET/CT for suspected disease progression. Imaging showed increased FDG uptake in the right lower lung mass and systemic lymphadenopathy (mediastinal, supraclavicular, axillary, paraaortic, and iliac regions). The appearance of a stable lymph node and a clinical history of IgG4 lymphadenopathy suggested an inflammatory process, although malignancy in the lung mass and mediastinal nodes could not be excluded. Lobectomy confirmed the presence of lung adenocarcinoma, while radical lymph node dissection identified IgG4-related lymphadenopathy without metastasis. This case underscores the need for considering differential diagnosis of PET-positive lymphadenopathy, especially in patients with comorbid conditions that mimic or coexist with malignancy.

Figure 1

A 73-year-old male with stage IA minimally invasive lung adenocarcinoma, a status confirmed post-surgical wedge resection at age 66, underwent ¹⁸F-FDG PET/CT due to suspected disease progression on routine 3-month chest CT follow-ups. The maximum intensity projection coronal PET (A) revealed low-grade FDG activity in the right lower lung (RLL) tumor mass (SUVmax 4.6; (B), white arrowhead). Multiple FDG-avid lymphadenopathies were identified, including the mediastinal, bilateral supraclavicular (largest node measuring 12 mm; (B), yellow arrows), bilateral axillary (largest node 18 mm on the left; (B), yellow arrowhead), paraaortic (12 mm; (B), white arrows), and iliac nodes, with the left axillary lymph node showing the highest SUVmax of 7.7. The absence of systemic organ involvement made metastatic disease less probable. Serial chest CT scans, including one performed at age 67 (C), consistently showed no significant changes in the size or appearance of the bilateral supraclavicular ((C); yellow arrows) and axillary lymph nodes ((C); yellow arrowhead), reducing the likelihood of malignant spread. The symmetrical and systemic distribution of the lymphadenopathy suggested benign etiologies, such as inflammatory or lymphoproliferative disorders. Differentiation between lymphoma and inflammatory lymphadenopathy can be guided by two PET/CT observations and three clinical indicators: a high SUVmax liver ratio, elevated SUVmax in retroperitoneal lymph nodes, older age, a reduced erythrocyte sedimentation rate, and a low platelet count [1]. Given the low probability of lymphoma and lack of clinical correlation, the patient’s FDG-avid lymphadenopathies were deemed inflammatory. Notably, at the age of 59, the patient was diagnosed with IgG4 lymphadenopathy, confirmed by a left axillary lymph node biopsy revealing IgG4-positive transformed germinal centers and elevated serum IgG4 levels. This history supports IgG4-related lymphadenopathy as a probable diagnosis. Although rare, both IgG4-related inflammatory pseudotumors mimicking primary lung cancer [2,3] and lung cancer concomitant with IgG4-related disease [4] have been reported. For this patient, the RLL tumor mass and mediastinal lymphadenopathy required further evaluation to exclude cancerous processes. Differentiation using PET/CT can be challenging, as these pseudotumors often exhibit SUVmax values ranging from 3.4 to 10, with associated mediastinal and hilar lymphadenopathy showing SUVmax values between 2.8 and 3.9, overlapping with early-stage NSCLC (median SUVmax 3.2, range 0.7–13.3) [5]. Nevertheless, PET/CT remains valuable for identifying multi-organ involvement in IgG4-related disease prior to treatment [6] and monitoring the response to prednisone-based therapy [7], potentially reducing the need for biopsies. The patient subsequently underwent lobectomy, which revealed an acinar predominant adenocarcinoma, pT2aN0M0, stage IB. Radical lymph node dissection confirmed IgG4-related lymphadenopathy without metastasis. Histopathology demonstrated Bcl2 negativity in germinal centers, IgD positivity in mantle cells and the marginal zone, and an IgG4+/IgG+ plasma cell ratio of 45%, consistent with IgG4-related lymphadenopathy. This case underscores the importance of integrating clinical history, imaging comparisons, and alternative diagnoses, particularly when malignancy coexists with mimicking conditions [8]. Correlating PET/CT findings with clinical context is essential for accurate diagnosis and management.

[Figure omitted. See PDF]

Author Contributions

Writing—original draft preparation, T.-C.T.; writing—review and editing, T.-C.T. and H.-P.C.; supervision, D.H.-Y.S. and C.-C.L. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Written informed consent has been obtained from the patient to publish this paper.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

1. Chen, J.; Xu, D.; Sun, W.-J.; Wang, W.-X.; Xie, N.-N.; Ruan, Q.-R.; Song, J.-X. Differential diagnosis of lymphoma with 18F-FDG PET/CT in patients with fever of unknown origin accompanied by lymphadenopathy. J. Cancer Res. Clin. Oncol.; 2023; 149, pp. 7187-7196. [DOI: https://dx.doi.org/10.1007/s00432-023-04665-7] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36884116]

2. Seip, T.; Calderón Novoa, F.; Valeo Chulvi, M.P.; Smith, D.; Dietrich, A. IgG4 inflammatory pseudotumor mimicking primary lung cancer. Rev. Fac. Cien. Med. Univ. Nac. Cordoba; 2023; 80, pp. 66-69. [DOI: https://dx.doi.org/10.31053/1853.0605.v80.n1.34753] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37018367]

3. Kitada, M.; Matuda, Y.; Hayashi, S.; Ishibashi, K.; Oikawa, K.; Miyokawa, N.; Ohsaki, Y. IgG4-related lung disease showing high standardized uptake values on FDG-PET: Report of two cases. J. Cardiothorac. Surg.; 2013; 8, 160. [DOI: https://dx.doi.org/10.1186/1749-8090-8-160] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23800259]

4. Ikebe, S.; Minami, S.; Ihara, S.; Yasuoka, H.; Komuta, K. Pulmonary Adenosquamous Cell Carcinoma with Systemic Lymphadenopathy due to Immunoglobulin G4-Related Disease: A Case Report. J. Med. Cases.; 2021; 12, pp. 164-171. [DOI: https://dx.doi.org/10.14740/jmc3649] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34434452]

5. Takeda, A.; Sanuki, N.; Fujii, H.; Yokosuka, N.; Nishimura, S.; Aoki, Y.; Oku, Y.; Ozawa, Y.; Kunieda, E. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy. J. Thorac. Oncol.; 2014; 9, pp. 65-73. [DOI: https://dx.doi.org/10.1097/JTO.0000000000000031] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24346094]

6. Tokue, A.; Higuchi, T.; Arisaka, Y.; Nakajima, T.; Tokue, H.; Tsushima, Y. Role of F-18 FDG PET/CT in assessing IgG4-related disease with inflammation of head and neck glands. Ann. Nucl. Med.; 2015; 29, pp. 499-505. [DOI: https://dx.doi.org/10.1007/s12149-015-0969-3] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25877159]

7. Zhang, J.; Chen, H.; Ma, Y.; Xiao, Y.; Niu, N.; Lin, W.; Wang, X.; Liang, Z.; Zhang, F.; Li, F. et al. Characterizing IgG4-related disease with ¹⁸F-FDG PET/CT: A prospective cohort study. Eur. J. Nucl. Med. Mol. Imaging; 2014; 41, pp. 1624-1634. [DOI: https://dx.doi.org/10.1007/s00259-014-2729-3] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24764034]

8. Lee, J.; Hyun, S.H.; Kim, S.; Kim, D.-K.; Lee, J.K.; Moon, S.H.; Cho, Y.S.; Choe, Y.S.; Kim, B.-T.; Lee, K.-H. Utility of FDG PET/CT for Differential Diagnosis of Patients Clinically Suspected of IgG4-Related Disease. Clin. Nucl. Med.; 2016; 41, pp. e237-e243. [DOI: https://dx.doi.org/10.1097/RLU.0000000000001153] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26914555]